Association of a decrease in antithrombin III activity with a perinatal elevation in aspartate aminotransferase in women with twin pregnancies: relevance to the HELLP syndrome.
OBJECTIVE
Decreased antithrombin III (AT-III) activity and/or thrombocytopenia associated with an elevated serum level of aspartate aminotransferase in late pregnancy can threaten the lives of both the mother and the fetus. We investigated whether antenatal declines in AT-III activity and the platelet count occur in late twin pregnancy and whether reduced AT-III activity and/or thrombocytopenia precedes an increase in the serum level of aspartate aminotransferase.


METHODS
The platelet count, AT-III activity, and the serum level of aspartate aminotransferase were determined weekly or biweekly in 237 women with twin pregnancies in a longitudinal and partly prospective study.


RESULTS
Both AT-III activity and the platelet count decreased gradually in the last month of pregnancy, irrespective of the presence or absence of clinical signs of pre-eclampsia. A perinatal elevation in aspartate aminotransferase occurred in 36 (15%) of 237 women. The risk of a perinatal elevation in aspartate amino-transferase increased as the antenatal AT-III activity and/or the platelet count decreased. Pre-eclampsia developed in 60 women (25%). The relative risk of a perinatal aspartate aminotransferase elevation (95% confidence interval) for the 60 women with pre-eclampsia, the 60 women with a platelet count < or = the 25th percentile (164 x 10(9)/1), and the 60 women with AT-III activity < or = the 25th percentile (76% of normal) was 1.9 (1.0 to 3.4), 4.1 (2.3 to 7.5), and 5.9 (3.2 to 11.1), respectively, compared with the remaining 177 women.


CONCLUSIONS
AT-III activity and platelet count gradually decreased in the last month of twin pregnancies. A perinatal aspartate aminotransferase elevation was preceded by marked decreases in these parameters in women with twin pregnancies. The monitoring of AT-III activity and platelet count in women who exhibit a gradual decline in these parameters may help to avoid the development of severe HELLP syndrome.
Minakami
H
H
Department of Obstetrics and Gynecology, Jichi Medical School, Tochigi, Japan. minasho@jichi.ac.jp
Watanabe
T
T
Izumi
A
A
Matsubara
S
S
Koike
T
T
Sayama
M
M
Moriyama
I
I
Sato
I
I
D000328:Adult; D000990:Antithrombin III / Q000032:analysis / Q000378:metabolism*; D001219:Aspartate Aminotransferases / Q000097:blood*; D002585:Cesarean Section; D005260:Female; D005865:Gestational Age; D017359:HELLP Syndrome / Q000097:blood*; D006801:Humans; D007231:Infant, Newborn; D008137:Longitudinal Studies; D010976:Platelet Count; D011225:Pre-Eclampsia / Q000097:blood; D011247:Pregnancy / Q000097:blood*; D011250:Pregnancy Complications, Hematologic / Q000097:blood; D011263:Pregnancy Trimester, Third; D012016:Reference Values; D018570:Risk Assessment; D013921:Thrombocytopenia / Q000097:blood; D014427:Twins
D000990:Antithrombin III; D001219:Aspartate Aminotransferases